What Biopact does

Biopact (legal entity: Biopact Ventures, LLC) is an Austin, Texas-based nanoscale biomaterials company that has developed MGMR® (Macromolecular Gatekeeper Release), a patented trans-membrane delivery vehicle consisting of hollow, biocompatible nanoscale tubules approximately 1/10,000th the width of a human hair. MGMR's tunable surface chemistry is engineered to load diverse molecular cargo — including oligonucleotides, peptides, proteins, and genetic materials — and deliver it intracellularly without compromising membrane integrity or inducing cytotoxicity. The technology is positioned as a cargo-agnostic, non-biologic alternative to existing transfection methods (lipid, viral, electroporation), with applications explicitly targeted at therapeutics and biopharma, biomanufacturing and cell manufacturers, agricultural biotechnology, and industrial biotech / cellular engineering. In a murine therapeutic model, MGMR loaded with doxorubicin concentrated in targeted tissues and extended cargo half-life; the company cites potential to reduce gene vector costs that represent ~30% of cell-therapy COGS (~$150K per batch). A dedicated sub-brand, Biopact CT (Cellular Transport), packages the MGMR platform specifically for cell therapy R&D and manufacturing customers.

The company operates with 1-10 employees and pursues a sales-led, consultative GTM through direct partnerships and custom-development engagements rather than a scaled distribution channel. Revenue mechanics combine technology platform licensing/royalties with research services and custom development, structured as a five-step engagement (Load, Transport, Release, Deliver, Implement) in which Biopact customizes MGMR surface chemistry for a partner's payload, measures release kinetics, and integrates the platform into the partner's process. Customer segments are diversified by use-case across four verticals, though no named customers, enterprise contracts, or revenue figures are disclosed. The only disclosed financing is a ~$1.04M round dated May 2021 from unknown investors. Core intangible assets include MGMR® as a registered trademark and underlying patents attributed to co-founders Kurt Swogger, Clive Bosnyak, and Kent Phelps.

Name

Biopact

Legal name

Biopact Ventures, LLC

Website

https://bio-pact.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Biopact develops MGMR®, a patented nanoscale tubule-based intracellular delivery vehicle for biomolecules. It serves therapeutics, biomanufacturing, agricultural biotech, and cellular engineering customers through direct licensing and custom-development partnerships from Austin, Texas.

Ownership category

akta.pro rank

Product category

Intracellular Delivery Technology (Nanoscale Biomaterials)

NAICS

Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821)

akta.pro primary industry

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)

akta.pro secondary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Intracellular delivery
• Nanoscale biomaterials
• Transfection technology
• Cell therapy manufacturing
• Biopharmaceutical delivery

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Platform Licensing and Partnership: Biopact appears to generate revenue through licensing its MGMR technology platform to pharmaceutical, biotechnology, and agricultural companies. The company works with partners to integrate MGMR into existing processes and develop customized applications.
2. Research Services and Custom Development: The company offers a structured process to test MGMR's delivery capability with customer payloads, including measuring release kinetics and determining performance improvements in the customer's system.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Biopact develops and licenses its patented MGMR® (Macromolecular Gatekeeper Release) nanoscale biomaterial platform — hollow nanoscale tubules engineered as a transmembrane delivery vehicle for biomolecules including proteins, nucleic acids, peptides, small molecules, and viruses. The platform is commercialized under the MGMR® product line and the Biopact CT sub-brand for cell therapy/biomanufacturing, and is offered to therapeutic developers, cell manufacturers, agricultural technology firms, and industrial biotechnology companies via technology licensing and custom development partnerships.

Product overview

Biopact is a nanoscale biomaterials company offering a unified product portfolio centered on MGMR®, a versatile intracellular delivery technology. MGMR® consists of hollow nanoscale tubules that enable efficient intracellular transport of diverse molecular cargoes including genetic materials, oligonucleotides, peptides, and proteins. The company operates two branded offerings: the core MGMR® product for broad intracellular delivery applications (therapeutics, biomanufacturing, agriculture), and Biopact CT (Cellular Transport), a specialized transfection technology sub-brand targeting cell therapy R&D and manufacturing. Both offerings leverage the same underlying MGMR nanotechnology platform with tunable surface chemistry for cargo loading and release.

Differentiator

Problem solved

Functional benefit

Brands

• Biopact CT: Biopact Cellular Transport Transfection Technology - a sub-brand focused on driving down time and cost of cell R&D and manufacturing through the MGMR transfection technology platform.

Products and services

• MGMR® (Macromolecular Gatekeeper Release) Platform

Quantifiable outcome

• In a murine therapeutic model, MGMR loaded with doxorubicin demonstrated rapid concentration in targeted tissues and extended half-life of molecular cargo
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• MaxCyte: MaxCyte is a leading electroporation-based transfection platform serving cell therapy, gene therapy, and biomanufacturing customers—the same core use cases Biopact targets with MGMR. Both companies sell platform transfection tools to therapeutic developers and CDMOs seeking standardized, scalable delivery into difficult cell types.
• Polyplus-transfection (Sartorius): Polyplus supplies PEI-based and plasmid DNA transfection reagents widely adopted in gene therapy and viral vector manufacturing. Its customer base and application areas (therapeutics and biomanufacturing delivery) overlap closely with Biopact's MGMR platform.
• Mirus Bio: Mirus Bio develops the TransIT line of transfection reagents used in cell therapy, gene therapy, and academic research—directly comparable in offering and customer profile to Biopact's MGMR. Like Biopact, the company sells delivery technology to biopharma and CDMO customers.

Broad incumbents

• Thermo Fisher Scientific (Lipofectamine): Lipofectamine is the dominant lipid nanoparticle transfection reagent used across research and biomanufacturing. Thermo Fisher's broader life sciences portfolio makes it a broad incumbent rather than a focused peer, but it competes head-to-head with MGMR wherever reagents are selected for transfection.
• Lonza Cell & Gene Technologies: Lonza operates one of the largest cell and gene therapy CDMO networks, with proprietary process technologies and transfection/transduction tools. It competes with Biopact CT at the integrated manufacturing solutions level for cell therapy developers.
• Bio-Rad Laboratories (Gene Pulser): Bio-Rad offers the Gene Pulser electroporation platform used widely in research and process development. As a large life sciences tools incumbent, it overlaps with Biopact in transfection technology positioning rather than as a focused competitor.
• Cytiva: Cytiva (formerly GE Life Sciences) supplies bioprocessing tools, transfection reagents (e.g., XtremeGene), and cell therapy manufacturing solutions. Its broad biomanufacturing portfolio overlaps with the customer base Biopact targets with Biopact CT.
• MilliporeSigma (Sigma-Aldrich transfection reagents): MilliporeSigma sells a broad catalog of transfection reagents and bioprocessing consumables. While not a focused competitor, it competes with MGMR wherever researchers and biomanufacturers source transfection tooling from incumbents.

Emerging players

• CureVac: CureVac develops mRNA therapeutics and works extensively with delivery technologies including lipid nanoparticles. While more focused on mRNA itself than delivery per se, it overlaps with MGMR in the nucleic-acid intracellular delivery space.
• Precision BioSciences: Precision BioSciences develops in vivo gene editing and cell therapy products that rely on efficient intracellular delivery of nucleases. Its delivery challenges and customer profile (therapeutic developers, CDMOs) overlap with Biopact's MGMR use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/biopact
• LinkedInlinkedin.com/company/bio-pact

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biopact